Simulations Plus, Inc. (SLP) To Go Ex-Dividend on July 29th

Simulations Plus, Inc. (NASDAQ:SLP) announced a quarterly dividend on Tuesday, July 2nd, NASDAQ reports. Shareholders of record on Monday, July 29th will be paid a dividend of 0.06 per share by the technology company on Monday, August 5th. This represents a $0.24 dividend on an annualized basis and a yield of 0.60%. The ex-dividend date of this dividend is Monday, July 29th.

Simulations Plus has a payout ratio of 31.6% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Simulations Plus to earn $0.71 per share next year, which means the company should continue to be able to cover its $0.24 annual dividend with an expected future payout ratio of 33.8%.

Simulations Plus Stock Performance

Shares of NASDAQ:SLP opened at $39.89 on Thursday. The firm has a market cap of $797.40 million, a price-to-earnings ratio of 75.26 and a beta of 0.72. The firm has a fifty day moving average price of $47.68 and a 200 day moving average price of $44.15. Simulations Plus has a fifty-two week low of $32.69 and a fifty-two week high of $52.69.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Tuesday, July 2nd. The technology company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.15 by $0.04. The business had revenue of $18.54 million for the quarter, compared to analysts’ expectations of $17.92 million. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The business’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.20 EPS. As a group, research analysts predict that Simulations Plus will post 0.55 earnings per share for the current year.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $45.95, for a total transaction of $919,000.00. Following the transaction, the director now owns 3,580,857 shares of the company’s stock, valued at approximately $164,540,379.15. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $45.95, for a total value of $919,000.00. Following the completion of the sale, the director now owns 3,580,857 shares of the company’s stock, valued at $164,540,379.15. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel L. Weiner sold 750 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $49.32, for a total value of $36,990.00. Following the transaction, the director now owns 7,009 shares of the company’s stock, valued at approximately $345,683.88. The disclosure for this sale can be found here. Insiders sold 44,500 shares of company stock valued at $2,072,198 in the last ninety days. Insiders own 20.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on SLP shares. William Blair assumed coverage on Simulations Plus in a report on Friday, June 28th. They set an “outperform” rating for the company. Oppenheimer boosted their price target on shares of Simulations Plus from $55.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 13th. Finally, Craig Hallum reiterated a “buy” rating and set a $56.00 price objective on shares of Simulations Plus in a research report on Wednesday.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.